Celcuity https://validator.w3.org/feed/docs/rss2.html Senior Manager/Associate Director, Statistical Programming Senior Manager, Clinical Data Management Senior Medical Director Senior Medical Director, DSPV Senior or Principal Scientist, Formulation and Process Development Senior Quality Assurance Auditor Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences Celcuity Inc. Announces $50 Million Private Placement Director, Medical Science Liaison, North Central (Chicago, Illinois) Director or Senior Director, API Development Executive Director, Regulatory Affairs, Global Senior Director, National Accounts and Field Reimbursement Lab Systems Manager Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024 Celcuity to Participate in Cowen’s 44th Annual Health Care Conference Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer Celcuity Appoints Eldon Mayer as Chief Commercial Officer Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium Associate Director, R&D Laboratory Associate Scientist, Cell Signaling and Assay Development Director, Medical Science Liaison, Carolinas Associate Director or Director, Clinical Scientist Associate Director, Process Engineering Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call Celcuity To Present at Upcoming Needham and Stifel Investor Conferences Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call Associate Director, Drug Safety and Pharmacovigilance Associate Director, Field Operations Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call Celcuity To Participate in Jefferies Global Healthcare Conference Celcuity Announces Pricing of Underwritten Common Stock Offering Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call Block Pam. Unlock Tomorrow